Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Citius Oncology, Inc.NASDAQ: CTOR
Capital Expenditures · Q2 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q2 FY2026 capital expenditures was -$5, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$14.
Context
- Capital expenditures increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near -$5 or moves back toward the trailing-twelve-month quarterly average of -$3.5.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (4) USD
- Year-over-year change
- +0.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (4) | +0.0% |
| FY2024 | 2024-09-30 | (4) | -200.0% |
| FY2023 | 2023-09-30 | 4 | — |
| FY2022 | 2022-09-30 | 0 | — |
Capital Expenditures vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 capital expenditures of $14 is the 8th largest of the 10 companies compared; the peer median is $77K.
- Its year-over-year change of +250.0% is the 3rd highest of 9, against a peer median of +40.5%.
- Capital expenditures amounts to 0.0% of revenue for CTOR, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5M | +171.5% | -44.9% | 79.1% | |
| LTM Mar 2026 | $4.17M | +599.6% | -44.1% | 3.9% | |
| LTM Mar 2026 | $2.88M | +380.7% | -59.9% | 8.5% | |
| LTM Mar 2026 | $758K | +119.1% | -51.9% | — | |
| LTM Mar 2026 | $218K | -38.1% | -70.5% | 19.0% | |
| LTM Mar 2026 | $77K | -45.8% | -10.3% | 0.1% | |
| LTM Mar 2026 | $55K | -40.2% | — | — | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $14 | +250.0% | — | 0.0% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6 | -220.0% | — | — |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CTOR) | $77K | +40.5% | -48.4% | 6.2% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Net Income | 380.81K | 2.42M | (21.15M) | (24.76M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 576K | 1.06M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 64.24K | 411.77K | 13.2M | 9.89M |
| Accounts Receivables | 25.99K | 349.05K | 0 | 0 |
| Inventory | 0 | 0 | (2.13M) | (12.65M) |
| Accounts Payables | 0 | 0 | 2.42M | 9.52M |
| Other Working Capital | 38.25K | 62.72K | 12.91M | 13.02M |
| Other Non-Cash Items | (493.02K) | (3.43M) | 7.5M | 8.32M |
| Operating Cash Flow | (47.97K) | (601.3K) | 126.35K | (5.49M) |
| Capital Expenditures | 0 | 4 | (4) | (4) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (67.32M) | (1.32M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (5M) | (5.75M) |
| Investing Cash Flow | (67.32M) | (1.32M) | (5M) | (5.75M) |
| Debt Repayment | 0 | 0 | 3.8M | 0 |
| Common Stock Issued | 68.04M | 0 | 0 | 15.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (383.84K) | 1.66M | 1.07M | 0 |
| Financing Cash Flow | 67.66M | 1.66M | 4.87M | 15.17M |
| Effect of Forex Changes | 0 | 0 | (32.75K) | 0 |
| Net Change in Cash | 289.18K | (256.43K) | (32.63K) | 3.92M |
| Free Cash Flow | (47.97K) | (601.3K) | 126.35K | (5.49M) |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.